X4 Pharmaceuticals (XFOR) 3 Nov 222022 Q3 Earnings call transcript

Greetings, and welcome to X4 Pharmaceuticals third quarter 2022 conference call. At this time, all participants are in a listen only mode. A question answer session will follow the formal presentation.

As a reminder, this conference call is being recorded.

It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. begin. Please

And Chief Presenting Ragan Executive Medical Diego operator. will today's and morning, Officer XX's be Officer Cadavid. good you, on everyone. call Chief Thank Dr. Paula

Commercial from and member interim Chief Murray company's briefly company Dr. incoming hear Officer also Baldry and will new We Chief Stewart. Officer Medical Mark board the

DiBiase. be Scientific remarks, Financial Mary Officer Chief we call Officer Following Operating by Taveras, open prepared Chief to your Mostafa, Chief joined the will questions Art and and will Adam Officer

most a call, and making development research As today's that XXQ, differ forward-looking including forecasted. results from recent is actual statements subject risks plans as which Description may with those can be the on company will uncertainties today. are to market reminder the well risks this close statements these regarding product after activities. and SEC, be cause in to filed quarter's regulatory to of filings These expected XX's be found as

to over the like I'd call Paula? President to and Dr. Ragan. now turn CEO Paula XX's

And everyone, morning. for this on call the you Dan. thank joining us Thanks,

the a shared few to And and role Chief the be our Chief As of his introduction. as and out in mentioned, end of board Rhythm consultant member, Diego will former today's we XX this will At release Dan transitioning words Officer CMO. Medical Dr. as call, Murray GSK Medical a senior and of of say joining Officer press interim medical Stewart, Pharmaceuticals, will becoming just morning, as Murray be XX.

focus making burden to there's chronic neutropenic to treatment the significant potential team including as therapy are a treat good where broad need with a believe we indication tolerability. of patient therapeutics with progress first an been mission we've low for WHIM and efficacious to of syndrome and oral population our with disorders, the new excited company we share As welcome members, the we we sharpen our develop that extremely

therapeutic in highlight progress US, provide syndrome represent a syndrome in oral has a and for to favorably severe three an we mavericksphore but the low of with counts, syndrome of to Today, neutropenia will appropriately in chronic transform trial the prepared approved, no are could global three studied ramp phase people updates standard in of with a new launch. being create With which care. mavericksphore's the WHIM pivotal is the and landscape on a Mavericksphore phase of patients for to of that be WHIM syndrome, how call believe our if to the approved the focus treatment into like commercial to neutropenia is we and opportunity other have the XX,XXX new approximately a [ph], system ongoing population WHIM considered getting diagnosed. counts, also how minute disorders. and sometimes WHIM those profoundly referred which to antibody production, as now with potential to low broader impact low immune favorably potentially neutropenic is patients WHIM as combined chronic patients combined has the We I'd a population Hypogammaglobulinemia. as and immunodeficiency well diagnosed and syndrome impact take to Lymphocyte potential with because that monocyte deficiencies. review not also immunodeficiencies to only believe is neutrophil WHIM mavericksphore are treatment

please. slide, Next

susceptibility more the H low manifestations counts, to as experts into one and utilized blood in Patients retention in neutrophils, and as white marrow bone variable decreased birth. severe M cell hypogammaglobulinemia, In the this with is WHIM examine of [myelocytesis], these HPV-associated and reliable WHIM explains range abnormally of neutropenia. by I, the of mentioned, cases, Patients increased in types neutrophil inputs most one leading for phenotype, monocytes. of immunoglobulin profoundly field, The diagnose syndrome diagnosing levels, Lymphocytes of disease the to the present total immunoglobulin WHI the range for represent low severe as infections, counts, syndrome. of and a in As WHIM of low multiple which complex Lymphocyte neutrophils addition immunodeficiency neutrophils, from can clinical and clinicians view look is and disease, chronic WHIM monocytes, a the According presentation this well the can referred called combined or presentations, to frequent panleukopenia. white from Lymphocytes many to ways of and the variable journey begin and to to levels. is includes W, counts and the I wart low blood impacting to M, cell low disease which which monocyte have people

potential As evolve a WHIM cancers, into Bone with to particular the always including related with susceptibility associated utilized panleukopenia, based be the and HPV journey, can infections papillomavirus, needle people not sepsis. done diagnostic may consequence pain procedure. biopsies this severe, this due experience to bacterial, it syndrome risk due infection and to of morbidity with marrow human by although of infections viral be which lifelong can in can fungal warts be refractory invasive

diagnosis in the marrow to evaluation, findings the WHIM microscopic the mature corroborate hyper Upon are hyper bone or of syndrome. neutrophils segmented important

genetic cascade, CXCRX. CXCRX clinical of new without mutations, such CXCRX associated gain identified disease Interestingly, called for with genes the look in knowledge patients was myelokathexis the but mutations often analysis testing used. function diagnosis is there most receptor syndrome assessment about of including as Genetic confirmational the to mutations and in a WHIM genetic initially mutations have was mutations. In before fact, the genetic with signaling

neutrophils individuals, despite CXCRX responses, alterations lack share these four in the mediated of of mutations. fact, functional CXCR In

any due WHIM history those family with the of mutations. a of Finally, disease dominant also autosomal nature the supports diagnosis CXCRX in ultimate syndrome to the individual patient for

approaches manifestations, bone and in including genetic to and knowledge multiple clinical abnormalities support via the earlier of medical community and facilitate mutations, the history WHIM We needs of of marrow, variable diagnosis the assessments. to family syndrome continue accurate the awareness pathologic

Importantly, spectrum the high levels, treat getting that the dose study with portion disease, the placebo-controlled there in for treatments poorly components Existing of or approved often registrational low tolerated completed to treat problems GCSF chronic phase WHIM WHIM, the the improve mavericksphore antibody address study are testing syndrome. addresses time of potential of disease. a the individual the three to injections first treatment in such randomized which cause recently We associated the root treatments use. immunoglobulin specifically is as a for no only which is targeted for to full of neutropenia, the with the specifically

Diego review our three supports that about pending study over we excited to Diego? I'll our historical design phase our why and trial it to now results. turn so data are pivotal

review briefly of registrational assessing design WHIM Thank mavericksphore the you, study trial, our as a potential Paula. global syndrome. now four WHIM treatment I'll of

double enrollment XX the randomized As We placebo control last and QX design countries. trial blinded completed study. the is a year of patients in enrolling XX from over Paula mentioned, with

enrolled XXX neutral agency visit now week and We less patients confirmed inclusion the than equal database have last to cells all are status field required XX controlled last diligently the period placebo for screening. criteria count that a completed patient or towards microliter absolute had during lock. per or working The

that cells current as neutropenia per pretreatment syndrome. the was the considered an in severity an that enrolled characterizes trial, cells XXX indicating entered the patients severe XX that microliter WHIM than the severely was agency ANC Recall study. of XXX average neutropenia, this microliter, per neutropenic indication For less population is the they of

voucher supports XX which XX potential the significant value Importantly, pediatric to were years PRV or us of of almost potential age, rare priority between company. approval half review of mavericksphore and to the receive the upon a patients disease enrolled for of pediatric

of in all or and were roll At OLE elected over continue into to open OLE. end treatment label participants than percent eligible the study. of the the the control to of placebo on extension more receive the Notably, mavericksphore eligible participants XX study, portion

We safety monitoring by are any to to [tolerability]. due trial. data study trial data continue which all the a the safety of endorsed regularly modifications the the board, protocol of from has Safety this ongoing of portion been collect without has monitored continuation from

As I is adjudication committee, to are soon lock last by trial. an reviewed blinded visiting now portion being of patient placebo the completed mentioned, and database last independent control we follow. have The the data

We top of line quarter three year. fourth in phase announcing this to the data expect continue

Next slide please.

hours safety absolute We XX is daily weeks. once with metric during XX counts or a Participants study's which have treatment a four period, potential as mavericksphore. every mavericksphore in over for to endpoint above for three the study and above patients threshold assess approximately weeks in threshold The of neutrophil measured is TAT WHIM or the or dosed first is for neutrophil assessment robust trial. a approach ALC. in either XX-hour to this ANC secondary period. XX-week is It neutropenia an for threshold phase TAT of series mavericksphore's ANC, time ANC. for The efficacy times placebo XX the of Lymphocyte counts endpoint metrics key was primary severe same Calculations the called ANC. once The absolute the follow TAT TAT above were time counts short, raise or TAT

TAT are suffer mounting are Lymphocytes WHIM BMT immune patients responses. from Lymphopenia mostly for effective and ANC who and important of that hypogammaglobulinemia for is recall Assessment key cells significant

levels draws amount to a series XX-hour are thresholds. via measured are the equal over in threshold Patients standard Time XX methods presents plotted that neutrophil Lymphocyte graph certain and undergo time The time to or how and above here versus of is above is frame threshold calculated. blood above up or time. hours a counts CVC time of

nootropics for cells X,XXX and for per XXX microliter cells Here, microliter per Lymphocytes.

is or assess One impact treatment. exploratory here, list during and endpoints, to are first listed the few both clinical category PROs. them of Finally, is of by the a placebo year secondary of there clinical comprehensive patient physician organized outcomes reported A category. and mavericksphore key of endpoints,

and is related category second The to warts. infections

prespecified provided the this over of is tolerability slides. on The and are reflects comprehensive vaccine, the a several will study by number in subgroup FDA more This There specifics consultations, analysis. and the third a to few response PK. category design share also fourth and guidance category we safety, robust and is

Next please. slide

As responded study, the our two success phase along three three tracking the phase on open design, see endpoint the patients between dose in not the results three the basis endpoints, is we you the the inform neutrophil the than in saw phase label study, results to the two our of three can subjects mirror to baseline trial. top TAT assumptions only of ALC study, phase for endpoints XXX-milligram and a the treatment two was primary three served Based retention trial, the the phase two closely for primary formed positive here, have confidence with secondary XX of this all WHIM high both extension ranged dose, mavericksphore phase the treatment with rate for blinded the greater and basis trial the approximately of that phase Increases Lymphocyte ANC also ANC the trial, and power The phase in phase the counts. of three but success. upon increased endpoint TAT on the as and percent. and enrolled In syndrome with phase XX hours. XX ALC the and power two which selected and

in the Importantly, burden. rate were observed outcomes. and and ANC infections wart of TAT including Reductions reported in the associated positive TAT benefit with patient phase these clinical two in ALC the trial increases both

indicated was the phase or with extension. of for WHIM. or was on Also, that phase award that Recall mavericksphore evidence treatment of tolerated study, the FDA study BTD long-term two results clinical FDA BTD the supported substantial equally significant resulted and breakthrough for data high demonstrate two importantly, mavericksphore hurdle in phase improvements therapy endpoints our recall over therapies. the from us drug And favorable the designation clinically The the for and required that endpoint throughout of preliminary well BTD that available two the for is syndrome. this in may the mavericksphore the granting WHIM a totality including shared

daily one's study. negative you her slide, This a patient was see on encasing in phase close In major of quality a words cancer and with of two long a On compound view study She large up, her of infections. specific mavericksphore large works this treatment history a the the her also part a of of reported thumb. and oral sinus participant participant had XX-year-old in life female refractory on risk. we provide frequent can nail this that the impact impact

more that dose. other the almost once lesions These can over daily Additional evident visibly The after lesions larger was time was wart were in during image This phase are her on warts the shows almost the most in We image of milligram many images the reductions shows across see completely of well. evident subject same Similar as areas her based were A after a this and The wart inpatient thumb with her over study. even feet. on hands two questionnaire. burden the sizes on her treated prior resolved. experiences interviewed reported global than XXX on an year left three change. captured infections dramatic of She overall and distributed improvement the years right was treatment. treatment. and or for a the impression lesions of subject's change PGIC favorable the reducing lesions the reported thumb wart to reduction patient as

reported and patient trial. We the have phase outcomes in included other assessment our three among PGIC physician

of syndrome, engagement formal context initiation ongoing FDA, and designation. with has agency the orphan of had with IMD the therapy an interactions the have breakthrough designation and our Since in please. we slide [ph] frequent drug under continued WHIM in mavericksphore the Next

the of primary later Importantly, syndrome our with are this FDA, works available key forward the analyzed, top the the share assessments. planned the the endpoints, plan FDA TAT has first data and that between related ANC data announcing ALC, the a endpoint the of difference and has provided have and to TAT optimize analysis. heterogeneity on and including and metrics variety results will size. followed include and WHIM XX composite along recognized us and infection with that for single to Once all endpoints line on endpoint, a the we [ph] provided informed have has They placebo endpoint liking into infections quarter. study trial guided our clear we secondary guidance by of to to combining design sample safety and the mavericksphore embided show potential assessments the looking trial guidance

turn to I'll Paula. back it now

believe make Based of and on treatment We on Syndrome. WHIM and commitment be diagnosis been an mavericksphore and the aged It treatment ongoing you, diagnosed discussions XX being Thank the we XX has awareness, syndrome syndrome. the support by positioned first the the patient medical Diego. focused to older of agency, expect label with ultimately in to history WHIM for our to is those WHIM education, communities. specifically developed our well of with

the a include examinations, the monocytopenia the combined and in various outlined consistent clinical described, previously as As of We've like history and immunodeficiency that the W, with of or more potentially diagnosis one of to H, investing of genetic lymphopenia, been support to neutropenia, recent or a marrow highlight assessments a bone information. WHIM and more as breadth phenotypes requires Hypogammaglobulinemia, and and assessment I family as M can and testing of a is clinical community here, activities in few I'd patient well efforts. setting

a could In for send the where potential place myelokathexis opinion, analyzed be we Center a such of pathology Myelokathexis syndrome. aid center a envision with marrow be the diagnosis of those can physicians begun a experienced expert samples future, establish to bone to WHIM second collaborating marrow in a with potential We've to bone a with by Excellence.

foundation, in a for U.S. Syndrome, the experts and patient a individuals believe breadth bringing International we we a companies and can more a and disease. kindred with Patient potential the as existing patient are potential establishing in syndrome. representatives, WHIM finally, registry community centers or members compliantly even within development genetic has or professional Additionally, this support we Organization XX in By people immunodeficiencies, community, across the Immunodeficiencies, education such physicians, for their engage together testing for a families academic including have amongst resource same abroad, registry patient to the WHIM of be WHIM patients IPOPI, excited family. to their And working great and who Primary with those global for the a directly hired medically about liaison, the support to patient drug trained for learn the to

our the I of now three see unblinding please. so hope trial for excited why slide, Next are phase we you can results.

in by about We partners successful follow. EMA part with a others an XX early commercial expect the U.S. countries. initially we of months, the to XXXX, is filing mavericksphore gearing European are the launch and seven consider top may phase U.S. second if focused already the and of half support Assuming launch to and up we territories the would if submission these five to markets approved, of launch of outside filing preparing mavericksphore for first expected approved, the be of key in NDA in to European for of half in the three, US follow our XXXX.

future have We potential will update point clarity when you into at a partnerships. we any

Next slide, please.

call actually As new at this Mark to couldn't XX, morning's we Baldry, are Sam welcome Mark's earlier, be Officer. on day Commercial Chief joined him. our pleased mentioned more is by Today and we first

in we WHIM and are on our someone in background critical to have us Mark, Mark of day first looking phase our four three your joining forward this at As ourselves trial. at with Mark XX as as is He's building skilled comes more are consider years than therapeutics. commercial in very innovating importantly, disease patients of Having teams, equally for Mark's to a unblinding our with global rare experience science evolution mavericksphore approach we operations. and up need. as commercial to our fortunate to We to in advance orphan the us time and multiple getting and particularly and passionate continuing coordinating to strategy XX. and corporate launched life about Welcome, program quick global speed background, readiness

to with you've opportunity commercial support pleased to to and hopefully a become the face forward launch of because efforts a I at can focused exciting able of much therapies. And digging just to of launching here, rare those syndrome, of as who Thank great with transform clearly outlined, such the XX world to career for new available I'm currently XX, living only disorders time the therapy therapeutics also standard This free were WHIM in. neutropenic is people innovative with become you, that help commercial an I around potential lives looking and Paula. be I'm diseases. its are and I've joined and to mavericksphore my who the first indication. not for patients for me with but considerable spent really mavericksphore challenges see the of chronic care first on

So, I'm and really whole team. looking forward with the you to working XX

are Mark. we, As Thanks.

Next slide, please.

As you mavericksphore ensure three would syndrome underway XXXX launch approved. preparing planned if anticipation the expect, WHIM phase for with market and of treatment and company to up product, the leading reaches the commercialization well is to patients the in data

mavericksphore and raise we leadership, are rate These to people patients of intend customer channels. on with want the preparation. commercial disease, rolling. educate I potential highlight office. we Baldry's activities phase commercial the some and to healthcare the several and Here, in Mark WHIM, spokes and and already professionals, the team people of this place to wheel team through of share medical phase, enter under the In actively planning additional patient recognizing build communities next PELs, engaged out PDLs communicating diagnosing pre of and and the mentioned field, to near-term getting the have the we awareness into and in building commercial and ongoing home it I've as in facing

gain of access payers We build the patients. the identify demonstrate we opportunities research may to value spectrum the to and issues access. and Mavericks capabilities and payer need that We've healthcare to and European for ensure understand with have also conducted U.S. begun full primary define market to

a partnerships registration well requirements, mavericksphore. have The FDA, and a the we manufacturing underway efficient front, distribution the network. are with have And chain marketing a for On secured been an core completed. key brand to and name ensure step exciting supply conditional specialty from standpoint, and lastly, approval stable batches of components commercial

patient potential market professional patient, have available most and are WHIM healthcare branding. physicians introduced HCPs early on research tools or a the awareness, on and likely WHIM conducted full have focused disease we developing a targeting Additionally, the to to

Next slide, please.

move WHIM in As will mavericksphore broader our The patient The neutropenia we same patients towards indications for support may to those WHIM, in foundations WHIM neutropenic be treat anticipated those chronic launching also physicians also future success time we syndrome neutropenic our towards commitment the support treat with like an with approval that community. improving chronic WHIM treat developing same patients chronic that and that highlight would potential that to leveraged disorders. disorders.

already seen fact, and these benefit In physicians. patients synergies we've

program neutropenias. diagnose WHIM to chronic neutropenic genetic called Path full other For has of patients example, free enabled new including Forward and congenital disorders, our across testing syndrome the physicians range

amended and diagnose, and One Additionally, additional translating the of we phase see further trials, support phase care anticipated three experts and the synergy our in manage into of expanding course, potentially CN network of patients. that medical BX for enrollment these our for

if expect market we interactions the bottom approved indication optimize leveraged channels line. for sales support our highly and drug to WHIM future payer and Finally, access our supply distribution for to

an Next neutropenia slide, If indication, We disorders. bright future the approved approved develop to array mavericksphore has to where that mavericksphore has we intend oral the for ahead. indications, for only WHIM continue chronic potential of believe to additional treatment in we it the become a believe please.

thus presented clinical in sustained of counts, neutrophil dramatic mavericksphore, we've various far. with patients the last the all trials, As CN the disorders over responding few seen we've and context all across studied including in to of increases years

chronic not WHIM that whether the maximize success we but idiopathic up plan currently we U.S. And phase potential result, meaningful are for in to cyclic congenital company set patients the has syndrome. launch disorders could could only also the generate to trial a U.S. in neutropenia could As and on up with cusp beyond a XXXX. in to XX, neutropenia revenue launch to XX,XXX support potentially study two begin that A of mavericksphore positive treat a diagnosed the to

with potential cadence three that followed WHIM CN data in CN us, phase quarter, of additional closing, data potentially on first starting In later see expect of and you mavericksphore of our we expected milestones initial half XXXX. ahead regulatory forward by the a path the clarity this transformative for steady can in

Assuming to forward positive of with half CN in a be registration following three WHIM, trial NDA on WHIM. ready in is our track phase phase filing XXXX, our we're advancing and the early expected mavericksphore NDA the for move filing second results for three to of and aiming

of WHIM As at ready beginning call, chronic transformation. to treatment believe is and landscape with change into XX this neutropenia, idiopathic mentioned And I mavericksphore we expanding starting is the this in poised the cyclic and neutropenia. congenital for

to launch and And one last career. GlaxoSmithKline wealth in We Dr. are like Rhythm officially Pharmaceuticals, Stewart guide thing CMO. multiple We'd development previous from rare conclude. welcome has throughout before our at of ready successful he the NDA filings helped Murray his CMO therapeutics to go. and He and as disease interim of has roles experience we a his

you with Murray would We are say to the on today. call time exciting few fortunate XX. during words? this us to for Murray, have is us him like a join

to as treatment to of years now, several the I'm and forward to unblind pleased submission. really at [export] phase this an with team excited as option whole to to been the data the three poised support important help patients. we're an company I'm part as to new XX quickly really Paula. the [story] Thanks, XX advance look able for Having working and NDA I'm possible bring time

the now open we your up Thank for why questions. Murray. don't you, Operator? call with that, And

Stephen Stifel. first [Operator ahead. with Instructions] Please question go from The Willey is

of appreciate of questions know terms the what it ahead also lymphopaenic what was and taking proportion for you was? as ALC pretreatment that pretreatment. update I happen were count average guess, and the the in of know I patients to severely the ANC well mentioned, patients of the average Thanks overview data. Do

I believe well. published think number, of the details. but as in I quite escaping an this abstract severely moment, think, lymphoenic us back in they we at my April some understanding are I is is The actual

So, we're happy offline that that sure get make you with and you to information. take

then to that's see infection curious been able not not the expectations? or whether I fine. can to that to, that's and and Just whether have of that's date? just been privy that information to up. you blinded or dig tracking trial the I to kind observed you're that's No, as guess rate in

So that. we blinded of look are one events, to any provide course, overall safety of are Diego to able I'll related which, infections them. on refer more at to context

monitored, yeah, we is said. that This the And, team infection have events. something has seen Paula as

blinded. Of we're completely course,

We have process out central actually finish working are help us. poise and the of adjudication, rigorous trial very will and to they to that, a that

we seen a You of one we've of somehow it's that several know, obviously, mitigated. the tracking, I clinical infections believe of the pandemic But, yes, has of benefit think number metrics that now we we among others. is what are with expect good impact that been consistent

guess, in the know XX,XXX bit little a opportunity being, And addressable estimated you're as the maybe I a then about talking but just, in had indicated that the that patients, think, I you thoughts range. proportion the disconnect gap picture I specifically? lastly, bigger of somewhere the question, that price previously I around then that was GCSF that in or know now you between think close patient XX,XXX does kind in of do how US, chronic numbers? your do who two into those X,XXX factor neutropenia maybe on were And range. this chronic you about How initial How mavericksphore the set? of number

disconnect. highlighting thank that things. Yes, a for couple you of Steve,

the really number out data. we on based registry that threw So, X,XXX previously was

very number of I setting, it's it one. commercial in average call So, doesn't And out difficult. course, what would the capture utility the really

many intermittently patients. used has GCSF So in

patient about you and of highlight, on based is how as only half also them for semi us surveys. chronic, consider chronic to our can we define another the on G, So challenge tolerate it number patients of

approach what well. Of course, we capturing not know as don't we're underneath that even

underserved I So, massively you for folks market is incredibly overall chronic with actually It's to about on daily that I'm size a painful the not on worried with market a treatment take the hear basis. a neutropenia. disconnect.

So, really think need further we something these opportunity. there's certainly lot patients To of new. uncover a who

understanding to the about that you're you're ways And away how having currently that decision from into pricing how factors thinking just decision? that with mavericksphore a make then still a on

I sensitivities are I we've XXs of numbers even WHIM think to enough appreciate thousands WHIM. around ultra-orphan done pricing price consistent the with relatively around even that mean, in

You the patients this thousands particular of certainly of in price into already molecules getting the know, there's the and that examples treatment. serve vertex commanding the points of with field that of XXs they CF

consideration think need of don't we the as really sort markets. that there's I about broader a of think neutropenia make deep So, to kind we

Cowen. next with The Eva question Privitera Please ahead. go from is

remind the war our of Can questions, enrollment taking [ph] any the trial? and assumptions, on Hi, Are powering thanks WHIM for assumptions you there us congrats given high the for all numbers? progress. updated this

said during TAT observed use for the the we As phase the context trial phase in trial. the the powering of ANC three call, changing two we the

So, the around increasing have to we concluded in took the at observed of patients there range, a consideration based that that that XX course two, least ANC on we needed XX was phase power, percent target but we into and minimum.

As ended we you heard, up XX. enrolling

have We retention. excellent

greater earlier for now the So is we that's our top secondary XX goes why primary percent, believe and endpoint the the right than we power on that said same endpoint.

disease. to neutral only because show really the that, not to but fields, core it's are this As that well that impacting as of we also goes Lymphocytes, important

you've And on new research genetic done, of WHIM? anything? the the on all the latest any there on what's or estimate Based are prevalence variants updates

the higher CXCRX, even coming come fascinating, to It's additional genes we X,XXX publications such out around mean, very to will of I continue comfortable some beyond syndrome. or that WHIM have with out feel with No, actually CXCRX. or guiding as be

to component. obviously, just as refine the we're think any beginning, we about further. updated keep we'll we you incredibly their excited potentially our at approach genetics which, diagnosis, that supporting a are physicians very of And is So,

The is next ahead. Mayank go Mamtani Riley from Please with Securities. question B.

look you. for to forward and questions, taking Thanks our with working

credit to any if Just if remind excluded just maybe characteristics the patients I which first comparing in what was required you you of that Could GCSF clinical versus for the or question, having just presentation great. permitted exposure baseline? would a could pediatric for three and here phase you a that support have us, any two? was cohort, patients as beyond be phase in between the bit remind study, for now And on three, also, give presentation treatment baseline have. and little didn't us if phase color And the more ongoing that, you you all phase the two prior you

question going I'm I you. got right here. this back your to a hope just repeat I to

sounds I and phase or two included or think similar in like fundamental there. since your question between three, pediatrics populations, your we've what's phase patient different between different

that that. highlight can use it think around how And Diego was the second was phase and element the I in So, addressed three. of GCSF then

it turn phase those over for I'll you So, questions. two to step Diego,

regarding So first question. the

quite So, and populations similar syndrome. phase phase three WHIM they're the in actually two required are sense all have to that

agency The a were counts mutation. pediatric to open of All XX, actually that actually The three up phase them we phase only difference XX identical. was to pretreatment almost had two CXCRX main adults. is while

You ask what type phenotype. of clinical

comes As earlier, in different WHIM ways. Paula mentioned

WHIM, to genetically So, clinically by had. be not have neutropenia, have whether diagnosed restrict letters. they with which to all had four we They confirmed, severe all and did or they they W had the

So much that we phase phase feel follows two. pretty three

is tolerated. intermittently, GCSF. it's used well not You ask mostly also about GCSF

the And allow don't that only doctors phase like use really we GCSF something of as much. three. in the WHIM So, therapy rescue it's

a mavericksphore have we're proud we very trial, blinded, of. mostly essentially, high randomized, fully that placebo very quality So

to want counts neutrophil Diego, ANC weren't on And we the we to that confounding just make took comment with use. GCSF sure you and TAT might approach

timing rescue to somebody If as GCSF therapy, received compounding. ANC we avoid of [ph] TAT the assessments the postponed the

mavericksphore, exposure thinking early had include would any also clarify, your so rash, was prior -- on to just you one had maybe patient because And which two, that also? he and to phase there

exposed seen of assessment, or We terms have enroll previously rashes we signals, anyone I dermatology been had on who much. mavericksphore. really in we not in to did we're safety not much seen based And blinded, two not blinded but phase have that. of mean,

as we did exclude anybody for Nor basis well. that

What how you undertake there, data regulators steps you'd on and neutropenia data And between available on there Could durability with early overlap also of connect the fronts? and dots there. kind filing lay becoming half. follow help filing then negation to is are forward second out multi NDA the any progressed two just then early that the WHIM the line the activities Could about the top talked up dose the of, side, the data. of if then chronic me, top line on my the interactions the excuse you these you after December in sort just

to piece - you're of evolutions of So, WHIM kind it kind trying sounds of together the various CN regulatory. and and

lay try to out those we'll clearly. So,

months take. about NDA, come data six phase So, give On in or the file an to will it QX. average, takes three

So putting as working moving there and, part closely the of forward with that's the as we're in second of course, excellent XXXX. in half We're shape agency terms in it it early of of where needed. just

been important a which takes months forward neutropenia, thing protocol course, with moving is of amended The of chronic of that, has always sites. completed. these couple the We're operationalizing around

think we data durability early some extension around study CM. we'll have the So, in in

phase one-year of will dosing lot data, Of have course, its WHIM course. three a durability the given

regarding approach trial. totality of be that the useful as chronic data So go a to registration will FDA we in neutropenia

but the isn't a So to regulatory happening tuned, data file thereafter complete plus conversations us shortly off then, on year CM and course, trial, should next plus the to registration kick three WHIM and clarity half first the that the WHIM, NDA prepare believe timing NDA. of advancing subsequent CN of finely phase to in we be

and your Great. Thanks you, for been adventure. it's All next for Diego. my great, working questions, with the best taking

with ahead. Allred question is next The Trevor Please go Oppenheimer. from

on be ask partnerships updates a might question Thanks. potential Walden to want just Strums. developing? here Any on that I

make as come progress. We'll back we update and

on We focus neutropenia. continue data upcoming to and on WHIM [excitement] the [prog]

else? Anything

ahead. with Wainwright, H.C. is The next go please question RK from

in needs your asked. trying line at And filing? will of before sense, analysis now want have updates questions presented be there what quarter? additional terms get an to just But a file and if else to to top the would And sort be you of of between the done DLA. out figure of I'm to trying get been have this announcement what my I data idea most

the top typically can line is appreciate, as you So primary endpoint plus safety.

secondary However, of endpoint the all highlight approach in effects the of there mavericksphore, immunodeficiency we're adding therapy our unique the specifically WHIM for to combined targeted first key syndrome.

usual. to forward than sharing bit little looking we're So more a

the entire that's for rights. preserve data incredibly publication to the important trial, of course, the terms of totality In of of

a So, provide a our publication, that. at when we an having rolling guidance and on medical we clarity NDA year. second try be more in via of And into submission the update to have I'll that next half do we'll think early then, we'll be relevant conference of course,

When or, the the in you this studies? four be updates the get WHIM update then chronic late neutropenia on those any will summer know, after you study next there focusing you would itself? through and diseases on chronic additional you're be that as clarity the get study at do point. we'll And And stated neutropenia think we on

bullish data medical updates CN what to with as for year. of a very we our really think we'll cut quickly forward first we CN trial. with trial all about the to plan moving under a that, this regulatory me work data the we half want registration take So trial on we provide and it's We're under clarity in really the exciting I or an us, of format additional conversations. quickly interesting it's the try some importantly, a But to so as next Again, can data support Most to as forward on to for totality conference. it. generate share possibly moving and we'll agency,

half updates look and to first those stay next providing in of So, year. forward we'll tuned the

quarter, with it's an And I good everything. exciting luck so know

Thank is you. It exciting. very

question-and-answer turn session. Ragan for I any closing conference to Paula to back remarks. the like over concludes the would This

additional Thank joining to past want A.M. make much I you now so XX:XX one since it's for today. did comment

our neutropenia XXXX As at been abstracts this accepted has an abstract published, presentation for year's just were very our meeting. announce probably on chronic phase to ASH study we're you that and know, oral happy one B

additional addition, we've of neutropenia, and on the on U.S. syndrome. had on these chronic of poster WHIM then and morphology and presentation, on prevalence, patient, accepted the the abstracts include additional and one other In several for voice two myelokathexis the one

concluded, a We you So, us. for wonderful with a to of and hope some in we're And I day. Orleans very New in everyone Thank you. December. ASH look that, seeing productive has forward

concludes This call. conference today's

and have Thank for lines. participating your disconnect a day. pleasant you may You